| Literature DB >> 30788013 |
Mohammed Qureshi1, Emily Gammoh1, Jawairia Shakil1, Richard Robbins1.
Abstract
The management of type 2 diabetes mellitus has evolved over the last several years as new antidiabetic agents continue to arrive and change the goals of diabetes care. In 2008, the U.S. Food and Drug Administration mandated that all new antidiabetic agents must demonstrate cardiovascular (CV) safety, which has led to a series of CV outcome trials. In this article, we review the key findings from these CV outcome trials and their impact on diabetes care guidelines.Entities:
Keywords: cardiovascular outcome trials; cardiovascular safety; diabetes management; major adverse cardiac events; type 2 diabetes mellitus
Mesh：
Substances：
Year: 2018 PMID： 30788013 PMCID： PMC6369620 DOI： 10.14797/mdcj-14-4-273
Source DB: PubMed Journal: Methodist Debakey Cardiovasc J ISSN： 1947-6108